BiotechTube

VXA-CoV2-3.1 + COMIRNATY® + VXA-CoV2-3.3

Phase 2Active
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV2

Conditions

SARS-CoV2, COVID-19

Trial Timeline

Oct 8, 2024 → Nov 1, 2026

NCT ID
NCT06672055

About VXA-CoV2-3.1 + COMIRNATY® + VXA-CoV2-3.3

VXA-CoV2-3.1 + COMIRNATY® + VXA-CoV2-3.3 is a phase 2 stage product being developed by Vaxart for SARS-CoV2. The current trial status is active. This product is registered under clinical trial identifier NCT06672055. Target conditions include SARS-CoV2, COVID-19.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06672055Phase 2Active

Competing Products

3 competing products in SARS-CoV2

See all competitors
ProductCompanyStageHype Score
Tocilizumab 20 MG/MLRochePhase 2
52
RemdesivirGilead SciencesPre-clinical
22
IMM-BCP-01 + PlaceboImmunomePhase 1
28

Other Products from Vaxart

Vapendavir + Vapendavir + PlaceboPhase 2
44
VXA-A1.1 + Fluzone®Phase 2
44
Vapendavir + Placebo Oral TabletPhase 2
44
VXA-CoV2-1.1-SPhase 2
44
BTA798 + PlaceboPhase 2
44